Syra Health Corp. Class A Common Stock (SYRA) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SYRA Revenue Growth
Revenue Breakdown (FY 2025)
SYRA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
SYRA Revenue Analysis (2020–2025)
As of May 8, 2026, Syra Health Corp. Class A Common Stock (SYRA) generated trailing twelve-month (TTM) revenue of $7.6 million, reflecting exceptional growth of +22.4% year-over-year. The most recent quarter (Q1 2026) recorded $2.3 million in revenue, up 31.1% sequentially.
Looking at the longer-term picture, SYRA's historical revenue data shows a 3-year CAGR of +8.8%. The company achieved its highest annual revenue of $8.0 million in 2024.
Revenue diversification analysis shows SYRA's business is primarily driven by Population Health (100%). With over half of revenue concentrated in Population Health, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TALK (+22.0% YoY), ACMR (+15.2% YoY), and CLOV (+48.7% YoY), SYRA has underperformed the peer group in terms of revenue growth. Compare SYRA vs TALK →
SYRA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SYRACurrent | $8M | +22.4% | - | -12.5% | |
 TALK | $229M | +22.0% | +24.6% | 1.4% | |
 ACMR | $901M | +15.2% | +41.9% | 12.1% | |
 CLOV | $1.9B | +48.7% | +23.4% | -4.4% | |
 LFMD | $194M | -6.2% | +39.1% | -4.0% | |
 OPRX | $109M | +18.8% | +20.4% | 10.7% |
SYRA Historical Revenue Data (2020–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.2M | -9.5% | $2.5M | 34.4% | $-904,324 | -12.5% |
| 2024 | $8.0M | +44.7% | $1.7M | 20.7% | $-3,764,885 | -47.2% |
| 2023 | $5.5M | -1.8% | $1.4M | 25.5% | $-2,887,599 | -52.4% |
| 2022 | $5.6M | +298.4% | $1.1M | 18.9% | $-2,089,695 | -37.2% |
| 2021 | $1.4M | - | $430K | 30.5% | $-3,280 | -0.2% |
| 2020 | $0 | - | $0 | - | $-4,267 | - |
See SYRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSYRA — Frequently Asked Questions
Quick answers to the most common questions about buying SYRA stock.
Is SYRA's revenue growth accelerating or slowing?
SYRA revenue is accelerating at +22.4% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $8M. Growth momentum has increased versus prior periods.
What is SYRA's long-term revenue growth rate?
Syra Health Corp. Class A Common Stock's 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +22.4% is above this long-term average.
How is SYRA's revenue distributed by segment?
SYRA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.